TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00991939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone USP Micronized
Description: The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
Study: NCT02457156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blumgart Anastomosis
Description: 1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cattell-Warren Anastomosis
Description: 1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
Study: NCT03289104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZipFix Sternal Closure System
Description: Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
Study: NCT00528528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Oval tablets containing 375 mg of telaprevir for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Oval tablets containing 375 mg of telaprevir for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Oval tablets containing 375 mg of telaprevir for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Oval tablets containing 375 mg of telaprevir for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2b
Description: Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2b
Description: Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) tablet
Description: Tablets containing 200 mg RBV for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) tablet
Description: Tablets containing 200 mg RBV for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) capsule
Description: Capsules containing 200 mg RBV for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) capsule
Description: Capsules containing 200 mg RBV for oral administration.
Study: NCT01589432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-639
Description: two 50 mg oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 3mg/kg infusion over 30 minutes
Study: NCT01578044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual care
Study: NCT02457156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
Study: NCT04436497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection
Study: NCT00194038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
Study: NCT02489682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-form written Informed consent information
Study: NCT00972725

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' HIV vaccine (732461)
Description: 1 dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HIV vaccine (732461)
Description: 1 dose intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One dose of 300 mg
Study: NCT02564185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Study: NCT05503342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma control assessment
Description: Asthma control assessment questionnaire application in paper format
Study: NCT05467384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5mg/day in two divided doses
Study: NCT05370053

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELF Test
Description: Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
Study: NCT02548338

Intervention type: PROCEDURE
Group type: OTHER
Intervention: argon plasma coagulation
Description: On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: argon plasma coagulation
Description: On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
Study: NCT02598440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants wil receive once-weekly oral alendronate (70 mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants wil receive once-weekly oral alendronate (70 mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants wil receive once-monthly oral ibandronate (150 mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Study: NCT01764555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 2 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 2 g
Study: NCT02393937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference: Metronidazole Gel 1%
Description: Participants are assigned to one of three groups in parallel for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: Metronidazole Gel 1%
Description: Participants are assigned to one of three groups in parallel for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Study: NCT00123123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate oral rinse (0.12%)
Description: chlorhexidine gluconate oral rinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate oral rinse (0.12%)
Description: chlorhexidine gluconate oral rinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01968330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go!®to sleep
Study: NCT01076036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath 200
Description: CorPath™ 200 robotically-assisted percutaneous coronary intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorPath 200
Description: CorPath PCI - robotic-assisted percutaneous coronary intervention
Study: NCT01004289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary angioplasty and stenting without additional intervention
Description: Primary angioplasty and stenting without additional intervention.
Study: NCT03777761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo for tucatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400mg single oral dose
Study: NCT01818102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Width 1000 HU/Level -450 HU
Description: Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Width 400 HU/Level 25 HU
Description: Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
Study: NCT00096434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02485561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health communication intervention
Description: This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health communication intervention
Description: This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education information
Description: Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information
Description: Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information
Description: Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
Study: NCT03718767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV Nivolumab
Study: NCT04115631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04498143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project SAVE (Stop Adolescent Violence Everywhere) SSI
Description: Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Supportive Therapy (Share Your Feelings) SSI
Description: Internet-based, 30-minute single session intervention to increase feelings disclosure.
Study: NCT04364360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane extract
Description: 2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
Study: NCT02303249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review of discharges and cross-sectoral video conferencing immediately after discharge
Description: The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
Study: NCT02545218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineorraphy
Description: Surgery for improperly healed perineal tear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercise
Description: Pelvic floor exercise tutored by physio therapist.
Study: NCT02915263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
Study: NCT01310764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trabeculectomy
Description: Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
Study: NCT02916901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04161937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention
Description: Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention
Description: Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
Study: NCT02728453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
Study: NCT01567111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 11C-Metomidate Positron Emission Tomography
Description: Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
Study: NCT00828230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: One application of 2mg budesonide once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo foam
Description: One application of placebo foam once daily for 8 weeks
Study: NCT01797055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human apotransferrin
Description: intravenous infusion
Study: NCT04696679

Intervention type: OTHER
Intervention: Patient Quality of life assessment
Description: Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France

Intervention type: OTHER
Intervention: Control group Quality of life assessment
Description: Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
Study: NCT02489682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-form written Informed consent information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Informed consent information